globenewswire.com · 22 jun

uniQure Announces $150 Million Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $150 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its ordinary shares on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

zacks.com · 22 jun

QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy

uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reductions and no serious safety events.

zacks.com · 19 jun

QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval

QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.

globenewswire.com · 19 jun

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~

seekingalpha.com · 18 jun

UniQure: AMT-130's FDA Path Reaffirms My Bull Case

QURE is now a more credible Huntington's disease gene-therapy story after the FDA reopened a near-term BLA path for AMT-130. The main bet is that AMT-130 could eventually become the first approved disease-modifying therapy for Huntington's disease. Also, QURE's balance sheet gives management time to pursue that BLA for AMT-130.

zacks.com · 18 jun

uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

seekingalpha.com · 17 jun

uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring

uniQure N.V. surges as the FDA now accepts Phase 1/2 data for AMT-130 as the primary basis for accelerated approval in Huntington's disease. QURE plans to submit its BLA for AMT-130 in Q3 2026, with a potential US market launch before year-end if granted priority review. Peak revenue potential for AMT-130 is now estimated (by me) at $1.5bn by 2030, supporting a bullish valuation case and suggesting up to 50% further upside.

investors.com · 17 jun

Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End

Biotech stocks climbed Wednesday after the Food and Drug Administration signaled the end of a "nail-biting journey" for UniQure.